In:
Digestion, S. Karger AG, Vol. 89, No. 1 ( 2014), p. 18-23
Kurzfassung:
Anti-epidermal growth factor receptor (EGFR) antibodies have been widely utilized as a standard treatment for metastatic colorectal cancer (CRC). Anti-EGFR antibodies bind competitively to EGFRs to inhibit receptor activation and subsequent signal transduction of the 〈 i 〉 RAS/RAF/MEK 〈 /i 〉 pathway and 〈 i 〉 PI3K/AKT 〈 /i 〉 pathway. By inhibiting EGFR-mediated signal transduction, anti-EGFR antibodies inhibit cell growth, invasion, metastasis and angiogenesis, and they induce apoptosis. The IgG1-type antibody cetuximab is also capable of inducing antibody-dependent cellular cytotoxicity. Several studies have shown that 〈 i 〉 KRAS 〈 /i 〉 mutation is a useful biomarker for predicting the efficacy of anti-EGFR agents, and the major guidelines for the treatment of CRC recommend the use of anti-EGFR antibody only for the cancers with wild-type 〈 i 〉 KRAS 〈 /i 〉 . Alterations of other genes, including 〈 i 〉 BRAF 〈 /i 〉 , 〈 i 〉 NRAS 〈 /i 〉 , 〈 i 〉 PTEN 〈 /i 〉 and 〈 i 〉 AKT 〈 /i 〉 , and EGFR expression/gene copy number have also been reported to be candidate biomarkers for predicting the efficacy of anti-EGFR agents. The predictive values of these biomarkers are still controversial and further investigations are required.
Materialart:
Online-Ressource
ISSN:
0012-2823
,
1421-9867
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2014
ZDB Id:
1482218-0
